Avinger-lumivascular-hero-mobile Avinger-lumivascular-hero-tablet
homepage_hero4_why_lumivascular

Combining real time intravascular imaging with therapeutic devices to
avoid damaging the native artery

VISUALIZATION.

Knowledge is power. The ability to see inside the artery during treatment gives physicians a lot more knowledge of the clinical problem and the power to do something about it in real time.

img-lumi-visual
  • ADVENTITIA

    The supportive and outermost layer of the artery is also the most sensitive to injury during treatment.

  • External Elastic Lamina (EEL)

    Science has proven that when this thin bright border is breached, the body may generate an aggressive healing response that leads to renarrowing of the artery.

  • Media

    The middle or muscular layer of the artery shows up as a dark band with OCT imaging.

  • DISEASE

    The deposits that cause the narrowing in the artery can easily be characterized and differentiated from the arteries natural structures because it’s non layered and amorphous.

PROVEN PRECISION.

The Lumivascular technology has generated some of the most compelling data
in the industry to date - proving that being able to see and treat at the same
time can provide best in class clinical outcomes.

vision ide 6 month
lumivascular ATHERECTOMY

130 PATIENTS | 20 SITES | 164 LESIONS

LUMINAL GAIN | 72%

  • 79%

    PRE-STENOSIS

  • 30%

    PANTHERIS STANDALONE

  • 22%

    POST-PANTHERIS +/- ADJUNCTIVE THERAPY

adventitia analysis

Adventitia

EFFICACY

Dissections

Safety

Perforations

follow-up comparative data
lumivascular ATHERECTOMY

freedom from tlr

SOURCE: VISION IDE (6 MONTH) & VISION INTERIM DATA
KM CURVE* (12, 24 MONTH)

  • 92%

    6 MONTH***

  • 86%

    12 MONTH

  • 82%

    24 MONTH

  • Amputations

FREEDOM FROM TLR & PATENCY**

SOURCE: EUROPEAN CASE SERIES (GRAZ, AUSTRIA)

  • 88%

    FREEDOM FROM TLR (12 MONTH****)

  • 86%

    PATENCY (12 MONTH****)

* VISION Interim Data included 55 patients on January 18, 2017

** Patency is defined as PSVR < 2.4

*** VISION IDE 6 Month data included the primary cohort only

**** European Case Series N=29 patients

CONNECT II DATA
LUMIVASCULAR CTO CROSSING

100 PATIENTS | 14 SITES | 100 LESIONS

Efficacy
Safety

LUMINAL CROSSING

  • 93%

    93% = TRUE LUMEN

  • 7%

    7% - SUBINTIMAL

Lumivascular Product Family